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Wound Botulism 
in Injection Drug 
Users
To the Editor: Infections are 
the most frequent and serious wound 
complications in injection drug users 
(IDUs). Wound botulism is primarily 
caused by Clostridium botulinum (1) 
and was ﬁ  rst observed in IDUs in New 
York in 1982 (2). It results from the 
introduction of C. botulinum spores 
into a wound and their multiplication, 
germination, in situ synthesis, and se-
cretion of toxin under anaerobic con-
ditions. Of 7 designated toxin types, 
neurotoxins A, B, E, and F result in 
human disease. During the 1990s, 
wound botulism cases among IDUs 
increased in the United States in con-
junction with the use of black-tar her-
oin (3). Since 2000, wound botulism 
cases in IDUs have been reported in 
Europe (4). To our knowledge, molec-
ular epidemiologic analyses have not 
been performed to conﬁ  rm suspected 
outbreaks. 
Within a 6-week period in Octo-
ber and November 2005, 12 clinical 
cases were recognized in the metro-
politan area of Cologne, Germany (5). 
Six patients were successfully treated 
at teaching hospitals of the University 
of Cologne. On admission, all socially 
nonrelated patients had signs of bilat-
eral symmetric cranial neuropathies 
such as ptosis, diplopia, blurred vision, 
dysphagia, dysarthria associated with 
symmetrical descending weakness of 
the upper extremities, and no sensory 
deﬁ   ciencies. Treatment of patients 
included administration of trivalent 
A, B, and E antitoxin; antimicrobial 
drugs such as penicillin G or mezlo-
cillin with metronidazole; and surgical 
drainage of any existing abscesses. 
Patient 1, a 31-year-old female 
IDU, had multiple abscesses on both 
legs. Four days after her admission, 
wound botulism was suspected and 
antitoxin administered. Respiratory 
failure required mechanical ventila-
tion for 11 weeks. Patient 2, a 51-year-
old male IDU, had 1 large abscess 
on the left lower leg. Antitoxin was 
administered within 3 days of hospi-
tal admission. Mechanical ventilation 
was required for 5 weeks. Patient 3, 
a 25-year-old male IDU, had a large 
abscess on the left forearm. Patient 
4, a 43-year-old man who used her-
oin intramuscularly, had an abscess 
of moderate size on the left forearm. 
Antitoxin was administered within 12 
hours of admission to patients 3 and 
4, and both patients required 2 weeks 
of respiratory support. Patient 5, a 32-
year-old male IDU who was positive 
for hepatitis C virus, had purchased 
heroin from the same dealer as patient 
2. Abscesses were absent. Antitoxin 
was administered within several hours 
of admission. Within 10 days, the pa-
tient recovered fully without need for 
mechanical ventilation. Patient 6, a 44-
year-old male IDU, had several skin 
lesions at injection sites on his arms, 
but no abscesses. He received anti-
toxin treatment within several hours 
of admission and was discharged with 
minimal residual neck weakness after 
7 days.
Serum specimens were obtained 
from patients 1, 2, 5, and 6. Botulinum 
toxin detected by the mouse bioas-
say in serum of patients 1 and 2, but 
not of patients 5 and 6, was neutral-
ized by polyvalent antitoxin (Novartis 
Behring, Marburg, Germany). Abscess 
specimens were available from patients 
2, 3, and 4. Anaerobic cultures grew 
C. botulinum, which was identiﬁ  ed 
by Gram stain, culture morphologic 
features, Rapid ID 32A (bioMérieux, 
Marcy l’Etoile, France), and 16S rDNA 
sequencing. All strains were suscep-
tible to penicillin G and metronida-
zole, as determined by the E-test (AB 
Biodisk, Solna, Sweden). PCR assays 
performed for C. botulinum type A, B, 
E, and F neurotoxin genes (6,7) identi-
ﬁ  ed the single toxin B. Toxin B produc-
tion was conﬁ  rmed by the mouse bio-
assay. Pulsed-ﬁ  eld gel electrophoresis 
(PFGE) after SmaI, SacII, and XhoI re-
striction (8) showed indistinguishable 
strains from patients 2, 3, and 4 (shown 
for SmaI in the Figure).
To our knowledge, this is the ﬁ  rst 
outbreak of wound botulism in IDUs 
that was conﬁ  rmed by molecular epi-
demiologic typing. PFGE suggests a 
Figure. Fingerprint patterns obtained for Clostridium botulinum isolates following pulsed-
ﬁ  eld gel electrophoresis after SmaI restriction show identical strains. Lane 1, 100-bp ladder; 
lanes 2–4, abscess ﬂ  uid isolates from patients 2, 3, and 4, respectively. LETTERS
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single-source exposure with C. botu-
linum type B in at least 3 IDUs; this 
implies that the heroin was obtained 
from a common source, where contam-
ination with C. botulinum spores may 
have been introduced when mixed with 
adulterants or diluted with substances 
such as dextrose or dyed paper. Skin 
popping (subcutaneous and intramus-
cular injection), which may increase 
the odds of wound botulism by a fac-
tor >15 (9), was used by all patients 
for drug delivery. This study conﬁ  rms 
previous observations that the duration 
of clinical symptoms before antitoxin 
administration affects the need for and 
duration of mechanical ventilation (10). 
Here, the time from hospital admission 
to antitoxin treatment ranged from 
several hours to 4 days and correlated 
with the mechanical ventilation inter-
val ranging from 0 days to 11 weeks. 
In addition, the extent of abscesses, 
which ranged from no abscesses to 
multiple abscesses, seems to affect 
clinical outcome. As soon as an index 
case of wound botulism in IDUs is di-
agnosed, a coordinated public health 
case-management effort, including 
hospitals, outpatient clinics, and infor-
mation centers for drug addicts, is man-
datory to alert the medical community 
and the drug users to consider wound 
botulism if typical symptoms occur and 
to enable the prompt administration of 
antitoxin. Obtaining tissue samples or 
abscess ﬂ  uid for culture and molecular 
epidemiologic studies of C. botulinum 
isolates is necessary to facilitate iden-
tiﬁ  cation of the source of the contami-
nated heroin.
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Multidrug-Resistant 
Acinetobacter 
baumannii
To the Editor: In the January 
2007 issue of Emerging Infectious 
Diseases, Sunenshine et al. (1) de-
scribed their ﬁ   nding of an indepen-
dent association between patients with 
multidrug-resistant (MDR) Acineto-
bacter infection and increased hospital 
and intensive care unit (ICU) length of 
stay compared with that for patients 
with antimicrobial drug–susceptible 
Acinetobacter infection. The authors 
did not, however, ﬁ  nd a statistically 
signiﬁ  cant difference in mortality rates 
between the 2 groups of patients.
Acinetobacter infections fre-
quently occur in severely ill ICU pa-
tients with other chronic illnesses or 
prolonged hospitalizations. We ana-
lyzed data for 27 neutropenic cancer 
patients with A. baumannii–associated 
bacteremia (15 with MDR and 12 with 
drug-susceptible A. baumannii infec-
tions) but no other chronic illness. We 
considered A. baumannii strains to be 
MDR if they were resistant to amika-
cin, meropenem, and ciproﬂ  oxacin. 
Univariate analysis (Epi Info 2000; 
Centers for Disease Control and Pre-
vention, Atlanta, GA, USA) showed 
that most of the bacteremic episodes 
were associated with certain risk fac-
tors, such as catheter insertion, neu-
tropenia, acute leukemia, and pre-
vious prophylactic treatment with 
quinolones or therapeutic treatment 
with cephalosporins or carbapenems 
(meropenem or imipenem) (Table).